




Quantifier la surcharge sodée du dialysé

Pr Sandrine Lemoine
Service de néphrologie, dialyse et physiologie rénale
Hôpital Edouard Herriot
Lyon

14 mai 2025

**ACTUALITÉS
NÉPHROLOGIQUES**
Jean Hamburger
HÔPITAL NECKER

NECKER SEMINARS IN NEPHROLOGY



RÉGULATION DE L'HOMÉOSTASIE HYDRO-SODÉE EN HD

Un challenge...


- ✓ Limiter la consommation en eau et en sel
- ✓ Ultrafiltration
- ✓ Prescription dialysat en sodium

KDIGO: Pas de consensus sur la prescription du sodium en dialyse

Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference






Jennifer E. Flythe^{1,2}, Tara I. Chang³, Martin P. Gallagher^{4,5}, Elizabeth Lindley⁶, Magdalena Madero⁷, Pantelis A. Sarafidis⁸, Mark L. Unruh⁹, Angela Yee-Moon Wang¹⁰, Daniel E. Weiner¹¹, Michael Cheung¹², Michel Jadoul¹³, Wolfgang C. Winkelmayer¹⁴ and Kevan R. Polkinghorne^{15,16,17}; for Conference Participants¹⁸



Flythe et al, *Kidney international*, 2020

PHYSIOLOGIE DU SODIUM ET LA THÉORIE DE GUYTON



Sodium osmotiquement actif

COMMENT QUANTIFIER CE SODIUM OSMOTIQUEMENT ACTIF?

4

Poids sec

OMI

Pression artérielle





Impedancemétrie



Biomarqueurs sanguins




PHYSIOLOGIE DU SODIUM: EVOLUTION DU CONCEPT?






Heer et al, Am J Physiol Renal physiol, 2000; Titze, renal AJP, 2008

DU MARS AU SODIUM CUTANÉE ...



PHYSIOLOGIE DU SODIUM: EVOLUTION DU CONCEPT?



→ Augmentation du contenu corporel en sodium

→ Pas de variation de poids




→ Pas de variation du secteur extra-cellulaire

→ Sodium non-osmotiquement actif suspecté

Rakova N, Juttner K, Dahlmann A, et al. Long-term space flight simulation reveals infradian rhythmicity in human Na(f1) balance. Cell metabolism 2013

PHYSIOLOGIE DU SODIUM: EVOLUTION DU CONCEPT?

8



PHYSIOLOGIE DU SODIUM: EVOLUTION DU CONCEPT?

Régime riche en sodium augmente la densité des capillaires lymphatique









Table 2. General parameters in healthy subjects during LS and HS diet

General parameters in healthy subjects ($n = 31$)



	LS	HS	P-value
Proteinuria (g/day)	<0.2	<0.2	-
Systolic blood pressure (mmHg)	123 ± 2	124 ± 1	0.138
Diastolic blood pressure (mmHg)	68 ± 1	69 ± 1	0.453
Mean arterial pressure (mmHg)	86 ± 8	87 ± 7	0.251
Creatinine clearance (mL/min)	103 ± 5	123 ± 5	0.003
NT-proBNP (pg/mL)	14 (11–19)	26 (20–35)	0.002
Body weight (kg)	79.9 ± 2.1	81.6 ± 2.1	<0.001
ECV (L)	19.8 ± 0.5	20.8 ± 0.5	0.023
Plasma VEGF-C (pg/mL)	773 (748–921)	881 (758–1023)	0.070
Total amount of VEGF-C (pg)	14539 (1002–22751)	18176 (14320–26405)	0.010
Plasma Na ⁺ (mmol/L)	138.5 ± 0.4	139.8 ± 0.4	0.00
Urinary Na ⁺ (mmol/day)	46 ± 11	257 ± 16	<0.00

LS = low-sodium diet, HS = high-sodium diet, Total amount of VEGF-C is calculated as plasma VEGF-C \times ECV. Reference value NT-proBNP < 125 ng/L



PHYSIOLOGIE DU SODIUM: EVOLUTION DU CONCEPT?



PHYSIOLOGIE DU SODIUM: EVOLUTION DU CONCEPT?



^{23}Na MRI : TECHNICALLY CHALLENGING



Mesure non invasive

Quantitative pour les organes superficiels

La sensibilité de l'IRM au sodium est d'env 10 % de celle du proton $[\text{Na}^+] \lll [\text{H}^+]$

Temps de scannage pour 1 image = 15 min

SPECTRO-RMN: IMPLICATIONS TECHNIQUES

15

De préférence sur des IRMs 3T

Contraintes techniques couteuses car:

La spectroscopie multinoyaux nécessite une **chaîne de radio-fréquence supplémentaire adaptée** en fréquence à chaque noyau étudié

Antenne de surface ou une birdcage double accord 1H/31P





→ Nécessite un ingénieur/physicien



Couplage images morphologiques (Proton) et fonctionnelle non invasive, quantitative ou semi-quantitative




²³NaMRI





LE SODIUM TISSULAIRE

Unpublished data, S. Lemoine and C.M McIntyre.

Age



Sexe



Kopp et al, hypertension, 2013

LE SODIUM TISSULAIRE, MRC, HD ET DP






FIGURE 4: Between-group comparison in mean tissue sodium concentration [(A) skin; (B) soleus and (C) tibia]. *P < 0.01; **P < 0.001; ***P < 0.0001.

LE SODIUM TISSULAIRE PEUT-IL ÊTRE MOBILISÉ?

With loop diuretic





Table 2. Demographic data and results.

Patients	
Gender	7 men/2 women
Age [years]	78 (range: 58–87)
Before Therapy	After Therapy
Muscle Na^+ [mmol/L]	30.7 ± 6.4
Skin Na^+ [mmol/L]	43.5 ± 14.5
Whole lower leg Na^+ [mmol/L]	44.7 ± 15.3
	24.2 ± 6.1
	32.2 ± 12.0
	29.9 ± 10.7


Hammon et al, Plos one, 2025

With SGLT2i



Karg et al. Cardiovasc Diabetol (2018)

LE SODIUM TISSULAIRE PEUT-IL ÊTRE MOBILISÉ EN DIALYSE ?



HD removes osmotic and non osmotic active sodium

METHOD

✓ hypothesis

Na dialysate prescription can modify tissular sodium content

Prospective observational study

NCT03004547



36 patients in HD > 3 mois



Randomised Evaluation of SODIUM dialysate Levels on Vascular Events

18 patients [137 mmol/L]



18 patients [140 mmol/L]



Mid week
Non dialysis day




Blood pressure



PATIENTS CHARACTERISTICS

	137 mmol/L	140 mmol/L
Age	66 yo (47-79)	65 yo (40-82)
% men	55%	66%
BMI (kg/m ²)	31,5 (21.6 – 41.1)	32.4 (21.4 – 43)
PAS/PAD	128/73 mmHg	133/79 mmHG
% Hypertension	83 %	88 %
% DT2	57 %	66 %
Dialysis vintage	19 months	22 months
Interdialytic weight	1.65 kg (0 – 3.2)	2.3 kg (0.1 – 5)



SODIUM 137 ET 140 MMOL/L PRESCRIPTION AND TISSULAR SODIUM CONTENT





→skin sodium content is significantly lower in [137] than [140] concentration

RELATIONSHIP BETWEEN SODIUM DIALYSAT AND TISSULAR SODIUM

On the whole Cohorts, n=50



BLOOD PRESSURE AND SODIUM CONTENT



→ Positive correlation between BP and skin sodium concentration

DO WE HAVE OTHERS PARAMETERS IN HD THAT COULD IMPACT TISSULAR SODIUM CONTENT ?


→ No impact of residual kidney function, dialysis vintage and vascular access.

QUELS IMPACTS SUR LE SODIUM TISSULAIRE DES PARAMÈTRES D'HD?

1) Durée longue d'HD associée à un régime strict en sodium (Tassin, France)

11 patients de Tassin vs 11 patients matchées en âge et sexe d'Allemagne

**La concentration cutanée de sodium est-elle du UF?
Sodium du dialysat?
Longueur du traitement?**




QUELS IMPACTS SUR LE SODIUM TISSULAIRE DES PARAMÈTRES D'HD?

2) Cohorte d'HD en Allemagne (n=75 patients)

- Part A: UF : 37 patients en HD UF <2.4 l vs 38 patients on HD > 2.4 l
- Part B: 41 patients HD < 4.5 hrs vs 34 patients HD >4.5 hours.
- Part C: 17 patients HD [Na]dialysat = 138 mmol/l vs 58 patients [Na]dialysat < 138 mmol/l.

QUELS IMPACTS SUR LE SODIUM TISSULAIRE DES PARAMÈTRES D'HD?


→ Part A: UF : 37 patients en HD UF < 2.4 L vs 38 patients on HD \geq 2.4 L



QUELS IMPACTS SUR LE SODIUM TISSULAIRE DES PARAMÈTRES D'HD?


31

Part B: 41 patients HD < 4.5 hrs vs 34 patients HD ≥ 4.5 hours.



QUELS IMPACTS SUR LE SODIUM TISSULAIRE DES PARAMÈTRES D'HD?

Part C: 17 patients HD [Na]dialysat = 138 mmol/l vs 58 patients [Na]dialysat < 138 mmol/l.



QUELS IMPACTS SUR LE SODIUM TISSULAIRE DES PARAMÈTRES D'HD?

33

Table 2. Clinical characteristics on substudies of local HD patient cohort

Characteristics	UF <2.4 l	UF ≥2.4 l	P-value	HD time <4.5 h	HD time ≥ 4.5 h	P-value	Dialysate Na ⁺ <138 mmol/l	Dialysate Na ⁺ ≥138 mmol/l	P-value
Demographics									
Individuals, n	37	38		41	34		17	58	
Age, yr	55.4 ± 14.9	57.1 ± 14.6	0.62	58.4 ± 13.3	53.7 ± 16.0	0.17	56.5 ± 16.1	56.2 ± 14.4	0.93
BMI, kg/m ²	26.7 ± 4.7	28.5 ± 5.0	0.12	27.3 ± 4.2	27.9 ± 5.7	0.62	28.9 ± 5.3	27.2 ± 4.8	0.22
SBP, mmHg	132 ± 17	140 ± 20	0.05	136 ± 19	137 ± 18	0.85	135 ± 22	136 ± 18	0.75
DBP, mmHg	72 ± 10	75 ± 12	0.39	72 ± 10	75 ± 12	0.35	70 ± 13	74 ± 11	0.16
HD-related parameters									
HD vintage, yr	2 (3.1)	4 (5.7)	<0.05	1.75 (3.5)	3 (5.5)	0.15	4 (6.4)	2.1 (4.5)	0.20
Treatment time, h	4.5 (1.25)	4.75 (1.0)	0.1	4.25 (0.5)	5.5 (2.5)	-	4.5 (0.75)	4.5 (1.3)	0.81
Residual diuresis, ml/d	500 (1500)	100 (500)	<0.01	500 (1000)	0 (500)	<0.05	200 (1000)	300 (1000)	0.86
IDWG, kg	0.8 ± 0.9	2.7 ± 1.1	<0.01	1.4 ± 1.2	2.1 ± 1.4	<0.05	1.8 ± 1.5	1.7 ± 1.3	0.84
Ultrafiltration, l	1.3 ± 0.7	3.2 ± 0.7	-	2.0 ± 1.0	2.7 ± 1.3	0.01	2.5 ± 1.5	2.2 ± 1.1	0.45
Dialysate Na ⁺ , mmol/L	138 (0)	138 (2)	0.95	138 (2)	138 (0)	0.55	135 (0)	138 (0)	-
Laboratory data									
Plasma Na ⁺ , mmol/l	138.6 ± 2.5	137.4 ± 2.6	<0.05	138.4 ± 2.5	137.5 ± 2.6	0.16	136.4 ± 3.0	138.4 ± 2.3	<0.01
Plasma K ⁺ , mmol/l	5.2 ± 0.7	5.7 ± 0.8	<0.05	5.4 ± 0.8	5.5 ± 0.7	0.54	5.5 ± 0.9	5.4 ± 0.7	0.85
BIS data	32	35		35	32		13	54	
Total body water, l	40.8 ± 7.9	39.3 ± 6.8	0.40	38.7 ± 7.6	41.5 ± 6.9	0.11	37.7 ± 6.7	40.6 ± 7.5	0.20
Extracellular water, l	19.4 ± 3.9	19.2 ± 3.3	0.83	18.7 ± 3.7	20.0 ± 3.0	0.15	18.7 ± 3.3	19.5 ± 3.6	0.46
Intracellular water, l	21.4 ± 4.5	20.1 ± 4.0	0.21	19.9 ± 4.3	21.5 ± 4.2	0.13	19.0 ± 3.9	21.1 ± 4.3	0.11
ratio ECW/ICW	0.92 ± 0.12	0.97 ± 0.14	0.08	0.95 ± 0.13	0.94 ± 0.14	0.51	0.99 ± 0.13	0.94 ± 0.13	0.15
Overhydration, l	2.1 ± 2.1	1.9 ± 1.5	0.73	1.8 ± 1.9	2.1 ± 1.7	0.76	1.7 ± 1.4	2.0 ± 1.9	0.51

QUELS IMPACTS SUR LE SODIUM TISSULAIRE DES PARAMÈTRES D'HD?

34





Figure 6. Study synopsis of interventional cross-over adaptation of dialysate $[Na^+]$. Upper panel: timeline of stepwise changes in dialysate $[Na^+]$ from 138 to 142 to 135 mmol/l with according visits 1 to 3. Lower panel: Representative ^{23}Na -MRI images of the left calf during visits 1 to 3. Calibration tubes with 10, 20, 30, and 40 mmol/l NaCl are situated below the leg; the brightness of the resonance signal reflects the Na^+ amount. ^{23}Na -MRI, ^{23}Na magnetic resonance imaging; a.u., arbitrary unit; BCM, body composition monitor.

Characteristics	Dialysate Na^+ 138 mmol/l <i>n</i> = 10	Dialysate Na^+ 142 mmol/l <i>n</i> = 10	Dialysate Na^+ 135 mmol/l <i>n</i> = 8	<i>P</i> value 138 vs. 142/ 142 vs. 135
	138 mmol/l	142 mmol/l	135 mmol/l	
Demographics				
Age, yr	50.5 ± 13.2	-	-	-
Body weight, kg	89.8 ± 14.5	89.9 ± 15.3	89.8 ± 14.6	0.80/0.74
HD-related parameter				
HD vintage, yr	5.6 (IQR 7.1)	-	-	-
Treatment time, h	7.0 (IQR 1.6)	7.4 (IQR 1.7)	7.4 (IQR 2.3)	0.34/0.67
Ultrafiltration volume, l	2.1 ± 1.6	1.9 ± 1.3	1.7 ± 0.9	0.62/0.83
Laboratory data				
Serum Na^+ , mmol/l	138.6 ± 4.4	138.8 ± 2.2	140.6 ± 3.0	0.78/0.12
Serum K^+ , mmol/l	5.5 ± 0.7	5.5 ± 0.7	5.7 ± 0.9	0.60/0.12
BIS data				
Total body water, l	46.7 ± 6.1	47.3 ± 6.1	44.9 ± 4.3	0.16/0.34
Extracellular water, l	22.0 ± 3.1	22.9 ± 3.8	20.9 ± 2.7	<0.05/0.11
Intracellular water, l	24.1 ± 2.9	24.4 ± 2.5	24.0 ± 2.2	0.60/0.09
ratio ECW/ ICW	0.90 ± 0.08	0.94 ± 0.09	0.87 ± 0.10	0.09/0.05



LE SODIUM TISSULAIRE A-T-IL UN IMPACT CLINIQUE ?

Relationship between skin sodium content and LVM (Schneider et al, JASN, 2017)




Figure 4. Relationship between skin sodium content and LVM.

SODIUM TISSULAIRE ET RISQUE CV EN HD

Methods

Observational study



Cohort:
Chronic HD/PD patients



Imaging:
Skin $[Na^+]$ with ^{23}Na MRI (Leg)



Follow-up:
Clinical outcomes
(death and MACE)
by skin $[Na^+]$ quartile

Results


n=52 patients

	Q ₁ (n=11)	Q ₂ (n=13)	Q ₃ (n=15)	Q ₄ (n=13)
Mean skin $[Na^+]$ (mmol/L)	17.4	25.7	31.7	46.1
Median follow-up (days)	546	505	588	544
Deaths (n)	1	3	4	7
MACE (n)	1	1	2	3


Cox regression for skin $[Na^+]$ (per 10 mmol/L)

Death:
R.I.P.
HR = 1.83
 $HR_{adjusted} = 4.01$

Death and MACE:
R.I.P.
HR = 1.72
 $HR_{adjusted} = 2.32$




A
Survival in 52 Dialysis Patients (42 HD, 10 PD)
Stratified by Skin $[Na^+]$ Quartiles



No. at risk:				
Q ₁	Q ₂	Q ₃	Q ₄	No. at risk:
11	10	10	3	Q ₁
13	11	10	4	Q ₂
15	14	12	7	Q ₃
13	10	9	4	Q ₄

B
Event-free Survival (All-cause Mortality + MACE)
in 52 Dialysis patients (42 HD, 10 PD)



Skin $[Na^+]$ - Q ₁
11
10
9
3
2

Skin $[Na^+]$ - Q ₂
13
11
10
4
3


Skin $[Na^+]$ - Q ₃
15
13
11
5
2

Skin $[Na^+]$ - Q ₄
13
10
7
3
3


FIGURE 2: Kaplan-Meier curves for overall survival (A) and event-free survival as a composite of all-cause mortality and MACE (B) after skin $[Na^+]$ quartile stratification.

RESULTATS CONFIRMÉS PAR UNE AUTRE ÉQUIPE




HD-related parameter			
HD vintage, years	1.6 (IQR 3.4)	2.5 (IQR 4.8)	0.22
HD technique	24 BHD/5 HDF	20 BHD/3 HDF	
Treatment time, h	4.5 (IQR 0.75)	4.75 (IQR 0.75)	0.39
Residual diuresis, mL/d	500 (IQR 950)	300 (IQR 500)	0.30
IDWG, kg	1.8±1.1	1.8±1.5	0.94
Ultrafiltration, L	2.2±1.1	2.3±1.2	0.71
Dialysate Na ⁺ , mmol/L	138 (IQR 3)	138 (IQR 0)	0.39
Dialysate bicarbonate, mmol/L	32 (IQR 3)	32 (IQR 3)	0.95
Laboratory data			
Plasma Na ⁺ , mmol/L	138±2	139±3	0.19
BIS data			
Total body water, L	38.2±5.9	40.6±7.7	0.25
ECW, L	18.7±3.2	20.0±3.4	0.18
ICW, L	19.5±3.2	20.6±4.6	0.37
Ratio ECW/ICW	0.96±0.12	0.99±0.11	0.43



“Chicken or egg”?: Is tissue Na⁺ overload involved in the development of CVD or does CVD itself lead to tissue Na⁺ retention?



SODIUM ET INFLAMMATION ?



LE SODIUM TISSULAIRE AUGMENTE DANS LES PATHOLOGIES INFLAMMATOIRES

Polyarthrite rhumatoïde









Fig. 3. Average 24 h systolic blood pressure was correlated significantly with skin sodium ($Rho=0.457$, $P=0.01$) in patients with RA. This was independent of age ($P_{adj}=0.04$).

Sclérose en plaques



Psoriasis



EN CONCLUSION

- Le sodium peut être mesuré en HD
- Le sodium cutané peut être mobilisable
- Le sodium cutané semble être prédicteur indépendant des évènements cardiovasculaires
- Le sodium tissulaire est sensible aux interventions thérapeutiques
- Sodium cutanée: cible pour amélioration de la survie ?
- Etude sur plus grosse cohorte nécessaire mais problème d'accessibilité de l'IRM

PERSPECTIVES

46



Mesure des variations de sodium tissulaire au cours de la séance

Module sodium



Mesure des variations de sodium tissulaire au cours de la séance

MERCI



www.chu-lyon.fr



HCL
**HOSPICES CIVILS
DE LYON**